Literature DB >> 25643726

Synthesis and Evaluation of Millepachine Amino Acid Prodrugs With Enhanced Solubility as Antitumor Agents.

Yuzhe Wu1,2, Dong Cao2, Fang Wang2, Liang Ma2, Ge Gao1, Lijuan Chen1,2.   

Abstract

A series of amino acid derivatives of millepachine were designed, synthesized, and evaluated for their solubility and antiproliferation ability against tumor. The glycine derivative compound 7a exhibited the best potency and possessed long-term inhibitory capability on cell viability. It was also confirmed that 7a could arrest the cell cycle at G2 /M phase and trigger apoptosis. Furthermore, indirect immunofluorescence staining revealed antitubulin property of 7a, which is consistent with the previously reported derivatives of millepachine. In vivo, 7a suppressed tumor growth in an MDA-MB-231 xenograft tumor model. In summary, the exploit of 7a was a successful approach directed by the concept of generating amino acid prodrugs with increased bioavailability.
© 2015 John Wiley & Sons A/S.

Entities:  

Keywords:  G2/M phase; antiproliferation; bioavailability; millepachine

Mesh:

Substances:

Year:  2015        PMID: 25643726     DOI: 10.1111/cbdd.12507

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  2 in total

1.  Isolation of Bioactive Rotenoids and Isoflavonoids from the Fruits of Millettia caerulea.

Authors:  Yulin Ren; P Annécie Benatrehina; Ulyana Muñoz Acuña; Chunhua Yuan; Hee-Byung Chai; Tran Ngoc Ninh; Esperanza J Carcache de Blanco; Djaja D Soejarto; A Douglas Kinghorn
Journal:  Planta Med       Date:  2016-06-09       Impact factor: 3.352

2.  Design, Synthesis, and Biological Evaluation of N14-Amino Acid-Substituted Tetrandrine Derivatives as Potential Antitumor Agents against Human Colorectal Cancer.

Authors:  Yu-Chan Wang; Rong-Hong Zhang; Sheng-Cao Hu; Hong Zhang; Dan Yang; Wen-Li Zhang; Yong-Long Zhao; Dong-Bing Cui; Yong-Jun Li; Wei-Dong Pan; Shang-Gao Liao; Meng Zhou
Journal:  Molecules       Date:  2022-06-23       Impact factor: 4.927

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.